Ever since the first intermediate host of Clonorchis sinensis was identified with Bulimus striatulus, it has been place to an important position in epidemics. One way to prevent Clonorchis sinensis is to exterminate Bulimus, which is itself the first intermediate host and there by to separate the life cycle of Clonorchis. In killing B. striatulus, nicotine sulfate and lindane have been chosen from insecticides which are widely used in farming areas. And then nicotine sulfate and lindane have been used to check their effectiveness in killing B. striatulus. In this experiment, the resistance of cercaria which parasites to B. striatulus has also been studied. Dipping method was used in the study. Nicotine sulfate and lindane have been used to check the mortality effect. Nicotine sulfate was used to check percentage of mortality in varied times. The existance of cercaria was tried only in nicotine sulfate. In the experiment of mortality effect of insecticides to B. striatulus and cercaria, the difference in killing rate and the resistance in different concentration and different length of time have been researched. It resulted as following: In the experiment with nicotine sulfate, the mortality increased with thicker concentration in the constant length of time. When compared the necessary liquid of nicotine sulfate and lindane in LD 50, nicotine sulfate was less used than lindane, but the mortality proved high. In the treatment to the same concentration of nicotine sulfate in different length of time, it proved that the longer period showed higher mortality. The mortality time required in LD 90 of nicotine sulfate was dependent on the concentration. And thicker concentration showed quicker effect. In the resistance of cercaria and B. striatulus to nicotine sulfate, the resistance of cercaria was proved to be stronger than that of B. striatulus.
parasitology-chemotherapy-helminth-trematode-Clonorchis sinensis ; Bulimus striatulus ; nicotine sulfate ; lindane

No abstract available.
Female ; Ovary* ; Teratoma*

Purpose: To investigate the effects of intravitreal bevacizumab injection combined with laser photocoagulation in patients with retinal microaneurysms. Methods: We retrospectively reviewed the medical records of 21 eyes of 21 patients who underwent intravitreal bevacizumab injection and/or laser photocoagulation to treat retinal macroaneurysms. Eleven eyes received the combination therapy (CT) and 10 eyes monotherapy (MT) (either bevacizumab injection or laser photocoagulation). Changes in visual acuity, central macular thickness, macroaneurysm size and location, blood pressure, and the lipid level were compared between the two groups. Results: The mean patient age was 74.0 ± 10.5 years and the mean study period 7.0 ± 5.3 months. The mean macroaneurysm diameter of the CT group was 480.00 ± 292.30 μm and that of the MT group 328.75 ± 87.09 μm. The diameter was significantly larger in the CT group (p = 0.002). The initial visual acuities were 0.91 ± 0.66 and 0.88 ± 0.83 in the CT and MT groups, respectively. At the 4-month follow-up, the visual acuities were 0.33 ± 0.26 and 0.17 ± 0.29 in the CT and MT groups, respectively, and had significantly improved only in the CT group (p = 0.042). The initial central macular thicknesses were 441.82 ± 226.81 and 541.63 ± 401.97 μm in the CT and MT groups, respectively. At the 4-month follow-up, the figures were 293.60 ± 46.10 and 269.00 ± 48.34 μm in the CT and MT groups, respectively, and had significantly decreased only in the CT group (p = 0.043). Compared to the initial findings, the proportion of patients whose final visual acuities improved by more than two lines were 73% and 40%, respectively, thus significantly higher in the CT group (p < 0.001). Conclusions Combined intravitreal bevacizumab injection and laser photocoagulation treatment of retinal macroaneurysms improve visual acuity and decrease macular thickness.

Purpose: Here, we report a case of benign concentric annular macular dystrophy associated with a visual field defect.Case summary: A 34-year-old woman presented with a visual field defect that was not accompanied by a deterioration in visual acuity. The patient’s best-corrected visual acuity was 1.25 in both eyes. No signs of anterior chamber inflammation were observed, and fundoscopy showed annular hypopigmentation at the fovea in both eyes. Annular hyperfluorescence was observed on fluorescein angiography due to the window defect. Automated perimetry demonstrated an annular paracentral scotoma in both eyes. The standard electroretinogram was normal, whereas optical coherence tomography showed a loss at the inner and outer boundaries of the foveal photoreceptors. The patient had no history of chloroquine or hydroxychloroquine intake, which excluded Bull’s eye maculopathy. The patient was observed without treatment for 2 years and no change was observed in her visual acuity or the appearance of the fovea. Conclusions Benign concentric annular macular dystrophy should be considered in patients with annular hypopigmentation at the fovea without deterioration in the visual acuity of both eyes.

Purpose: To investigate the effects of intravitreal bevacizumab injection combined with laser photocoagulation in patients with retinal microaneurysms. Methods: We retrospectively reviewed the medical records of 21 eyes of 21 patients who underwent intravitreal bevacizumab injection and/or laser photocoagulation to treat retinal macroaneurysms. Eleven eyes received the combination therapy (CT) and 10 eyes monotherapy (MT) (either bevacizumab injection or laser photocoagulation). Changes in visual acuity, central macular thickness, macroaneurysm size and location, blood pressure, and the lipid level were compared between the two groups. Results: The mean patient age was 74.0 ± 10.5 years and the mean study period 7.0 ± 5.3 months. The mean macroaneurysm diameter of the CT group was 480.00 ± 292.30 μm and that of the MT group 328.75 ± 87.09 μm. The diameter was significantly larger in the CT group (p = 0.002). The initial visual acuities were 0.91 ± 0.66 and 0.88 ± 0.83 in the CT and MT groups, respectively. At the 4-month follow-up, the visual acuities were 0.33 ± 0.26 and 0.17 ± 0.29 in the CT and MT groups, respectively, and had significantly improved only in the CT group (p = 0.042). The initial central macular thicknesses were 441.82 ± 226.81 and 541.63 ± 401.97 μm in the CT and MT groups, respectively. At the 4-month follow-up, the figures were 293.60 ± 46.10 and 269.00 ± 48.34 μm in the CT and MT groups, respectively, and had significantly decreased only in the CT group (p = 0.043). Compared to the initial findings, the proportion of patients whose final visual acuities improved by more than two lines were 73% and 40%, respectively, thus significantly higher in the CT group (p < 0.001). Conclusions Combined intravitreal bevacizumab injection and laser photocoagulation treatment of retinal macroaneurysms improve visual acuity and decrease macular thickness.

Purpose: This study aimed to determine the changes in choroidal thickness induced by pioglitazone in diabetic patients. Methods: A total of 261 patients diagnosed with type 2 diabetes who had taken oral pioglitazone for more than 6 months were included in the study. After excluding patients who did not undergo regular eye examinations or who had ophthalmic surgery/interventions during the treatment period, a total of 40 eyes were included. The study examined the duration and dosage of pioglitazone, patient age, ocular axial length, refraction, glycated hemoglobin, systolic blood pressure, corrected visual acuity, macular thickness, choroidal thickness, and choroidal vascular index. Patients were categorized into a high-dose group if their pioglitazone dose was 30 mg or more per day, and a low-dose group if it was 15 mg or less. Choroidal thickness was measured below the subfovea and a 500 µm radius nasal and temporal to that location. Results: Choroidal thickness significantly increased after 6 and 12 months of pioglitazone (6.70 and 13.65 µm, respectively) in all subjects. When stratified by pioglitazone dosage, choroidal thickness increased at 6 and 12 months in both high-dose group (4.48 and 0.84 µm, respectively) and low-dose groups (6.85 and 21.45 µm, respectively), with a greater change observed in the low-dose group (p < 0.05). Based on the location of choroidal thickness measurements, a significant increase in choroidal thickness was observed at 6 and 12 months of pioglitazone treatment in the subfoveal (7.00 and 13.15 µm, respectively) and nasal regions (6.43 and 19.24 µm, respectively), while a significant increase was only observed after 6 months of treatment in the temporal region (8.53 µm, p < 0.05). The largest increase in choroidal thickness was observed in the nasal side. Conclusions This study found that choroidal thickness increased in diabetic patients after taking pioglitazone. Regular eye examinations are recommended for diabetic patients who are on pioglitazone.

Background: This study aimed to elucidate the potential usefulness of the medial rectus muscle of cadavers for research on satellite cells. Methods: Twenty-four medial rectus muscles were obtained from 12 cadavers. The control group included six medial rectus muscles from three live adults without brain activity. The muscle fiber diameter and distribution of satellite cells were measured and compared. Immunohistochemistry for myosin heavy chain and the transcription factor PAX7 was performed, and the distributions of myocytes and satellite cells were evaluated. Results: The average muscle fiber diameter was 142.18±36.49 μm in the cadaver group and 149.34±15.26 μm in the control group, and there was no significant difference between the two groups (p=0.38). The ratio of PAX7(+) cells to the number of muscle fibers was 0.056±0.015 in the control group and 0.006±0.006 in the cadaver group, reflecting a significant difference (p<0.05). Conclusions The medial rectus muscles of cadavers can be helpful in studying anatomical morphology; however, their usefulness in muscle satellite cell research appears to be limited.

Purpose: This study aimed to determine the changes in choroidal thickness induced by pioglitazone in diabetic patients. Methods: A total of 261 patients diagnosed with type 2 diabetes who had taken oral pioglitazone for more than 6 months were included in the study. After excluding patients who did not undergo regular eye examinations or who had ophthalmic surgery/interventions during the treatment period, a total of 40 eyes were included. The study examined the duration and dosage of pioglitazone, patient age, ocular axial length, refraction, glycated hemoglobin, systolic blood pressure, corrected visual acuity, macular thickness, choroidal thickness, and choroidal vascular index. Patients were categorized into a high-dose group if their pioglitazone dose was 30 mg or more per day, and a low-dose group if it was 15 mg or less. Choroidal thickness was measured below the subfovea and a 500 µm radius nasal and temporal to that location. Results: Choroidal thickness significantly increased after 6 and 12 months of pioglitazone (6.70 and 13.65 µm, respectively) in all subjects. When stratified by pioglitazone dosage, choroidal thickness increased at 6 and 12 months in both high-dose group (4.48 and 0.84 µm, respectively) and low-dose groups (6.85 and 21.45 µm, respectively), with a greater change observed in the low-dose group (p < 0.05). Based on the location of choroidal thickness measurements, a significant increase in choroidal thickness was observed at 6 and 12 months of pioglitazone treatment in the subfoveal (7.00 and 13.15 µm, respectively) and nasal regions (6.43 and 19.24 µm, respectively), while a significant increase was only observed after 6 months of treatment in the temporal region (8.53 µm, p < 0.05). The largest increase in choroidal thickness was observed in the nasal side. Conclusions This study found that choroidal thickness increased in diabetic patients after taking pioglitazone. Regular eye examinations are recommended for diabetic patients who are on pioglitazone.

Background: This study aimed to elucidate the potential usefulness of the medial rectus muscle of cadavers for research on satellite cells. Methods: Twenty-four medial rectus muscles were obtained from 12 cadavers. The control group included six medial rectus muscles from three live adults without brain activity. The muscle fiber diameter and distribution of satellite cells were measured and compared. Immunohistochemistry for myosin heavy chain and the transcription factor PAX7 was performed, and the distributions of myocytes and satellite cells were evaluated. Results: The average muscle fiber diameter was 142.18±36.49 μm in the cadaver group and 149.34±15.26 μm in the control group, and there was no significant difference between the two groups (p=0.38). The ratio of PAX7(+) cells to the number of muscle fibers was 0.056±0.015 in the control group and 0.006±0.006 in the cadaver group, reflecting a significant difference (p<0.05). Conclusions The medial rectus muscles of cadavers can be helpful in studying anatomical morphology; however, their usefulness in muscle satellite cell research appears to be limited.

Purpose: This study aimed to determine the changes in choroidal thickness induced by pioglitazone in diabetic patients. Methods: A total of 261 patients diagnosed with type 2 diabetes who had taken oral pioglitazone for more than 6 months were included in the study. After excluding patients who did not undergo regular eye examinations or who had ophthalmic surgery/interventions during the treatment period, a total of 40 eyes were included. The study examined the duration and dosage of pioglitazone, patient age, ocular axial length, refraction, glycated hemoglobin, systolic blood pressure, corrected visual acuity, macular thickness, choroidal thickness, and choroidal vascular index. Patients were categorized into a high-dose group if their pioglitazone dose was 30 mg or more per day, and a low-dose group if it was 15 mg or less. Choroidal thickness was measured below the subfovea and a 500 µm radius nasal and temporal to that location. Results: Choroidal thickness significantly increased after 6 and 12 months of pioglitazone (6.70 and 13.65 µm, respectively) in all subjects. When stratified by pioglitazone dosage, choroidal thickness increased at 6 and 12 months in both high-dose group (4.48 and 0.84 µm, respectively) and low-dose groups (6.85 and 21.45 µm, respectively), with a greater change observed in the low-dose group (p < 0.05). Based on the location of choroidal thickness measurements, a significant increase in choroidal thickness was observed at 6 and 12 months of pioglitazone treatment in the subfoveal (7.00 and 13.15 µm, respectively) and nasal regions (6.43 and 19.24 µm, respectively), while a significant increase was only observed after 6 months of treatment in the temporal region (8.53 µm, p < 0.05). The largest increase in choroidal thickness was observed in the nasal side. Conclusions This study found that choroidal thickness increased in diabetic patients after taking pioglitazone. Regular eye examinations are recommended for diabetic patients who are on pioglitazone.